1. Please comment on FDA’s proposed strategies for selectively testing blood donations from donors at risk for malaria using an FDA-licensed NAT.

   Strategy 1A: Selective testing for history of malaria, history of prior residence in malaria-endemic country, history of travel to a malaria-endemic area

   Strategy 1B: One-time testing of all donors and selective testing for history of malaria and history of travel to a malaria-endemic area

2. Please comment on FDA’s proposal that blood establishments should implement time-limited NAT screening of all donations collected in area(s) of the U.S. when a single case of local mosquito-borne malaria is reported by public health authorities.